Daniel E Cohen Selected Research

Therapeutics

4/2021	T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy.
1/2020	Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
12/2019	Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
1/2019	Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.
1/2019	Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
6/2016	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
3/2015	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
1/2014	Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
7/2013	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
1/2013	Exploratory study of oral combination antiviral therapy for hepatitis C.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel E Cohen Research Topics

Disease

18	Infections 01/2021 - 08/2006
8	Fibrosis (Cirrhosis) 01/2020 - 01/2014
5	Chronic Hepatitis C 01/2019 - 07/2013
4	Acquired Immunodeficiency Syndrome (AIDS) 04/2021 - 03/2008
4	Coinfection 01/2020 - 06/2003
3	HIV Infections (HIV Infection) 04/2021 - 01/2020
3	Hepatitis C 01/2020 - 01/2013
3	Chronic Renal Insufficiency 02/2019 - 06/2016
2	Chronic Kidney Failure (Chronic Renal Failure) 02/2019 - 06/2016
2	Kidney Diseases (Kidney Disease) 02/2019 - 02/2019
2	Anemia 01/2018 - 06/2016
1	Virus Diseases (Viral Diseases) 01/2021
1	Mental Disorders (Mental Disorder) 12/2019
1	Substance-Related Disorders (Drug Abuse) 12/2019
1	Liver Diseases (Liver Disease) 02/2019
1	Hemolytic Anemia 01/2018
1	Sarcoma (Soft Tissue Sarcoma) 08/2015
1	Stroke (Strokes) 08/2015
1	Viremia 03/2015
1	Body Weight (Weight, Body) 01/2014
1	Disease Progression 03/2007
1	Acute-Phase Reaction 07/2004

Drug/Important Bio-Agent (IBA)

19	paritaprevirIBA 01/2020 - 01/2013
18	Ritonavir (Norvir)FDA Link 01/2020 - 01/2013
17	ombitasvirIBA 01/2020 - 01/2014
16	Antiviral Agents (Antivirals)IBA 04/2021 - 01/2013
16	dasabuvirIBA 01/2020 - 01/2013
15	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2013
7	InterferonsIBA 01/2019 - 01/2013
5	Pharmaceutical PreparationsIBA 01/2021 - 08/2015
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2017 - 03/2015
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2014 - 01/2013
2	EpitopesIBA 03/2007 - 07/2004
1	HLA-DR Antigens (HLA-DR)IBA 04/2021
1	Raltegravir Potassium FDA Link 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Human immunodeficiency virus 1 p16 proteaseIBA 01/2020
1	Cytochrome P-450 CYP2B1 (PROD)IBA 01/2020
1	Lipopolysaccharide ReceptorsIBA 01/2020
1	ledipasvirIBA 01/2019
1	SofosbuvirIBA 01/2019
1	QuartzIBA 01/2019
1	Inosine TriphosphataseIBA 01/2018
1	TabletsIBA 01/2017
1	Erythropoietin FDA Link 06/2016
1	Clindamycin (Cleocin)FDA LinkGeneric 02/2008
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 02/2007
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2007
1	HLA-A3 Antigen (HLA A3 Antigen)IBA 07/2004
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 06/2003

Therapy/Procedure

11	Therapeutics 04/2021 - 02/2007
2	Duration of Therapy 01/2020 - 01/2017
1	Renal Dialysis (Hemodialysis) 06/2016
1	Highly Active Antiretroviral Therapy (HAART) 03/2008
1	Ambulatory Care (Outpatient Care) 08/2006